ProPhase Labs, Inc. Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net
ProPhase Labs, Inc. (PRPH) had Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net of $12.67 million as of 2021-08-10, per its 10-Q filed 2022-05-13.
Discontinued › Notes › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet · last filed 2022-05-13
- 2021-08-10: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $12.67M.
- 2020-10-23: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $2.50M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net |
|---|---|
| 2021-08-10 | $12.67M 10-Q · filed 2022-05-13 |
| 2020-10-23 | $2.50M 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |